Danaher Corporation (DHR) is a Medical - Diagnostics & Research company in the Healthcare sector, currently trading at $198.61. It has a SharesGrow Score of 67/100, indicating a above average investment profile with 4 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of DHR = $221.74 (+11.6% from the current price, the stock appears fairly valued). Analyst consensus target is DHR = $254 (+27.8% upside).
Valuation: DHR trades at a trailing Price-to-Earnings (P/E) of 38 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 4.52.
Financials: revenue is $24.6B, -7.1%/yr average growth. Net income is $3.6B, growing at -19.8%/yr. Net profit margin is 14.7% (healthy). Gross margin is 60.9% (+0.7 pp trend).
Balance sheet: total debt is $18.4B against $52.5B equity (Debt-to-Equity (D/E) ratio 0.35, conservative). Current ratio is 1.87 (strong liquidity). Debt-to-assets is 22.1%. Total assets: $83.5B.
Analyst outlook: 31 / 42 analysts rate DHR as buy (74%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 32/100 (Fail), Growth 15/100 (Fail), Past 100/100 (Pass), Health 100/100 (Pass), Moat 86/100 (Pass), Future 79/100 (Pass), Income 55/100 (Partial).
